AU2017366515B2 - Piperidine-2,6-diketone derivative and treatment for Crohn's disease - Google Patents

Piperidine-2,6-diketone derivative and treatment for Crohn's disease Download PDF

Info

Publication number
AU2017366515B2
AU2017366515B2 AU2017366515A AU2017366515A AU2017366515B2 AU 2017366515 B2 AU2017366515 B2 AU 2017366515B2 AU 2017366515 A AU2017366515 A AU 2017366515A AU 2017366515 A AU2017366515 A AU 2017366515A AU 2017366515 B2 AU2017366515 B2 AU 2017366515B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salts
dione
dioxopiperidin
isoindolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017366515A
Other languages
English (en)
Other versions
AU2017366515A1 (en
Inventor
Guanghuai Zeng
Hesheng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Hemay Pharmaceutical SCI Tech Co Ltd
Ganzhou Hemay Pharmaceutical Co Ltd
Original Assignee
Tianjin Hemay Pharmaceutical SCI Tech Co Ltd
Ganzhou Hemay Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Pharmaceutical SCI Tech Co Ltd, Ganzhou Hemay Pharmaceutical Co Ltd filed Critical Tianjin Hemay Pharmaceutical SCI Tech Co Ltd
Publication of AU2017366515A1 publication Critical patent/AU2017366515A1/en
Assigned to TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD, GANZHOU HEMAY PHARMACEUTICAL, CO., LTD reassignment TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD Request for Assignment Assignors: TIANJIN HEMAY BIO-TECH CO., LTD
Application granted granted Critical
Publication of AU2017366515B2 publication Critical patent/AU2017366515B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017366515A 2016-11-24 2017-11-23 Piperidine-2,6-diketone derivative and treatment for Crohn's disease Active AU2017366515B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611041317 2016-11-24
CN201611041317.5 2016-11-24
PCT/CN2017/112669 WO2018095378A1 (zh) 2016-11-24 2017-11-23 哌啶-2,6-二酮衍生物以及克罗恩氏病的治疗

Publications (2)

Publication Number Publication Date
AU2017366515A1 AU2017366515A1 (en) 2019-06-13
AU2017366515B2 true AU2017366515B2 (en) 2021-01-21

Family

ID=62194806

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017366515A Active AU2017366515B2 (en) 2016-11-24 2017-11-23 Piperidine-2,6-diketone derivative and treatment for Crohn's disease
AU2017366514A Active AU2017366514B2 (en) 2016-11-24 2017-11-23 Piperidine-2,6-dione derivative and treatment for ulcerative colitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017366514A Active AU2017366514B2 (en) 2016-11-24 2017-11-23 Piperidine-2,6-dione derivative and treatment for ulcerative colitis

Country Status (7)

Country Link
US (4) US11485724B2 (enExample)
EP (2) EP3546450A4 (enExample)
JP (2) JP7143296B2 (enExample)
CN (2) CN108101886A (enExample)
AU (2) AU2017366515B2 (enExample)
CA (2) CA3045703C (enExample)
WO (2) WO2018095377A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108101886A (zh) 2016-11-24 2018-06-01 天津和美生物技术有限公司 哌啶-2,6-二酮衍生物及其在治疗溃疡性结肠炎中的用途
CN108727319A (zh) * 2018-09-05 2018-11-02 常州大学 一种3-硝基邻苯二甲酸酐的制备方法
CN109293631B (zh) * 2018-11-30 2020-05-08 常州制药厂有限公司 3-氨基-n-(2,6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
CN111320604B (zh) * 2020-04-22 2021-02-09 牡丹江医学院 一种治疗小儿口腔黏膜疾病的化合物、制备方法及其用途
CN118370746A (zh) * 2024-04-25 2024-07-23 江苏省中医院 马尿酸在制备溃疡性结肠炎治疗药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070480A1 (es) * 2001-03-01 2002-09-12 Fundacion Universitaria San Pablo Ceu Derivados de glutarimida como agentes terapeuticos
CN1844118A (zh) * 2005-04-07 2006-10-11 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物
CN1961876A (zh) * 2005-11-08 2007-05-16 北京恩华医药研究院 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CN100488959C (zh) 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
CA2538864C (en) * 2003-09-17 2013-05-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
MX2007008903A (es) 2005-01-25 2007-09-07 Celgene Corp Metodos y composiciones que usan 4-amino-2-(3-metil-2,6- dioxopiperidin-3-il)-isoindol-1,3-diona.
ES2664872T3 (es) * 2010-06-18 2018-04-23 Taiho Pharmaceutical Co., Ltd Moduladores PRPK-TPRKB y sus usos
SG11201507759WA (en) 2013-04-02 2015-10-29 Celgene Corp Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
CN108101886A (zh) 2016-11-24 2018-06-01 天津和美生物技术有限公司 哌啶-2,6-二酮衍生物及其在治疗溃疡性结肠炎中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070480A1 (es) * 2001-03-01 2002-09-12 Fundacion Universitaria San Pablo Ceu Derivados de glutarimida como agentes terapeuticos
CN1844118A (zh) * 2005-04-07 2006-10-11 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物
CN1961876A (zh) * 2005-11-08 2007-05-16 北京恩华医药研究院 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Berlin, A. Ya. et al. "Derivatives of 3-amino-2,6-piperidinedione" Khimiya Geterotsiklicheskikh Soedinenii (1969), (4), 652-4 *
Brana, Miguel Fernandez et al. "Discovering a new analogue of thalidomide which may be used as a potent modulator of TNF-α production" European Journal of Medicinal Chemistry (2009), 44(9), 3533-3542 *
CAS RN 710935-25-4, STN Entry Date 6 July 2004 *
CAS RN 937844-56-9. STN Entry Date 19 June 2007 *
CAS RN 937844-57-0, STN Entry Date 9 June 2007 *
CAS RN 937844-58-1, STN Entry Date 19 June 2007 *
Cheng, J et al, "Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos", International Journal of Nanomedicine, (2011-09-15), vol. 6, pages 2007 - 2021. *
Kampmann, Sven S. et al. "The synthesis and fluorescence profile of novel thalidomide analogues" Tetrahedron (2015), 71(42), 8140-8149 *
Kovacs, Kalman et al. "Synthesis of glutamine and pyroglutamylglutamine derivatives substituted in carboxamide nitrogen" Acta Physica et Chemica (1966), 12(3-4), 143-50 *

Also Published As

Publication number Publication date
JP2020500205A (ja) 2020-01-09
JP2020500204A (ja) 2020-01-09
WO2018095377A1 (zh) 2018-05-31
US12331030B2 (en) 2025-06-17
JP7143296B2 (ja) 2022-09-28
JP7143295B2 (ja) 2022-09-28
EP3546450A4 (en) 2020-06-10
CA3045703A1 (en) 2018-05-31
CA3045703C (en) 2021-11-02
US20220372013A2 (en) 2022-11-24
AU2017366514B2 (en) 2021-01-21
US11873287B2 (en) 2024-01-16
US20190352277A1 (en) 2019-11-21
EP3546449A4 (en) 2020-06-10
US20220306600A1 (en) 2022-09-29
WO2018095378A1 (zh) 2018-05-31
US11485724B2 (en) 2022-11-01
CN108101887A (zh) 2018-06-01
EP3546450A1 (en) 2019-10-02
AU2017366514A1 (en) 2019-06-13
CN108101886A (zh) 2018-06-01
AU2017366515A1 (en) 2019-06-13
US20240132466A1 (en) 2024-04-25
CA3049161A1 (en) 2018-05-31
CA3049161C (en) 2023-03-07
EP3546449A1 (en) 2019-10-02
US20190389835A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
AU2017366515B2 (en) Piperidine-2,6-diketone derivative and treatment for Crohn's disease
CN111662281B (zh) 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途
CN109912598B (zh) 防治炎症反应的核苷类衍生物及其应用
WO2017189613A1 (en) Methods of using fasn inhibitors
KR102646322B1 (ko) 이소인돌 유도체
EP3368543A1 (en) Oxysterols and hedgehog signaling
JPS61275274A (ja) 1,3−ジチオ−ル−2−イリデン誘導体及びその用途
TWI839385B (zh) 肥胖症的治療
WO2006007794A1 (en) Cis-1,2-substituted stilbene derivates and the use thererof for manufacturing medicaments for treating medicaments for treating and/or preventing diabetes
CN110698491A (zh) 2-(喜树碱-10-氧基)乙酰胺类化合物和应用
KR100544901B1 (ko) 5-리폭시게나제 억제용 약학적 조성물
DK149769B (da) Analogifremgangsmaade til fremstilling af trans-4-(n-(substitueret-benzyliden)aminomethyl)-cyklohexan-1-carboxylsyre og derivater heraf
CN120757534A (zh) 喹唑林类化合物及其用途
CN115068473A (zh) 小檗碱型吡啶甲酸类季铵盐化合物抗病毒感染病的用途
CN101811974A (zh) 4-(3-(二甲氨基)丙氧基)-3,5-二甲氧基苯甲酸、其制法及医药用途
HK40047978A (en) Isoindole derivative
WO2019160926A1 (en) Compounds comprising short-chain fatty acid moieties and compositions and methods thereof
WO2015180693A1 (zh) 氨荒酸铋(ⅲ)配合物及其制备方法和用途
JP2018521107A (ja) Hiv感染を予防または治療するためのベツイン誘導体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GANZHOU HEMAY PHARMACEUTICAL, CO., LTD

Free format text: FORMER APPLICANT(S): TIANJIN HEMAY BIO-TECH CO., LTD

Owner name: TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD

Free format text: FORMER APPLICANT(S): TIANJIN HEMAY BIO-TECH CO., LTD

FGA Letters patent sealed or granted (standard patent)